Given the increase in the aging population, the prevention of cognitive decline in healthy older adults deserves close attention. Mild cognitive impairment affects 10%–25% of people over the age of 70 years. Mild cognitive impairment involves cognitive decline beyond that normally expected in a person of the same age with preservation of function. Dementia is defined as cognitive decline in one of several cognitive domains, along with difficulty in functional abilities. The annual rate of conversion from mild cognitive impairment to dementia is about 10%. Given this rate, in combination with the aging population, it is estimated that the prevalence of dementia will double to more than 1 million Canadians over the next 25 years.

A summary of our search strategy is outlined in Box 1. Our search included randomized controlled trials (RCTs) involving participants with normal cognition. We also searched for RCTs involving participants with mild cognitive impairment. Given the substantial differences between people with normal cognition and those with mild cognitive impairment, this review focuses on people with normal baseline cognition, which constitutes most of the older population.

The prevention of cognitive decline is an important concern for many older adults. There are many organizations and industries that target the public with claims that use of their products will prevent cognitive decline. These products range from physical and cognitive programs to prescription and nonprescription medications. The evidence to support use of these products is sparse, and both the public and clinicians find it challenging to identify which strategies might be effective in preventing cognitive decline. Often, the data regarding these interventions are conflicting, and the studies are of poor quality. The objective of our review is to clarify the evidence with a comprehensive review of high-quality published studies that investigated strategies to prevent cognitive decline in healthy older adults, for the purpose of providing guidance to older adults and their clinicians. We defined cognitive decline as any decline found by neuropsychiatric testing or increase in the incidence of mild cognitive impairment or dementia.

What pharmacologic interventions might be effective in preventing cognitive decline in older adults?

There is no strong evidence for the use of any pharmacologic interventions to prevent cognitive decline in healthy older adults (Table 1). However, there is some evidence of harm with certain pharmacologic therapies, including estrogen therapies and anti-inflammatory drugs.

Cholinesterase inhibitors and N-methyl-D-aspartate glutamate receptor antagonists

Cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists are approved for use in patients with dementia in an attempt to slow down cognitive and functional decline. Three RCTs investigated the effects of cholinesterase inhibitors or NMDA receptor antagonists for preventing cognitive decline in cognitively normal older adults. Cholinesterase inhibitors prevent the breakdown of acetylcholine, a chemical involved in neurotransmission, by inhibiting acetylcholinesterase. The NMDA receptor antagonists are thought to selectively block the excitotoxic effects associated with abnormal transmission of glutamate. A total of 89 patients were included in these trials, and follow-up ranged from 3 to 15 months. One study investigating donepezil included 20 patients and showed improvement in immediate ($p = 0.012$) and delayed ($p = 0.006$) semantic recall at 10-week follow-up, with no changes in immediate and delayed superficial recall. The

---

**Key points**

- There is no consistent evidence of benefit for any pharmacologic agent in preventing cognitive decline in healthy older adults.
- Studies investigating estrogen therapies and anti-inflammatory medications have shown evidence of a decline in memory.
- The evidence for physical activity in preventing cognitive decline is weak.
- Formal cognitive training exercises may have a benefit in preventing cognitive decline.
2 other RCTs investigated donepezil and memantine, and showed no evidence of improved memory or cognition.6,7

Hormonal therapies

Estrogen

Seven RCTs investigated the effects of estrogen and its derivatives, including 4 trials coordinated by the Women’s Health Initiative Memory Study (WHIMS) group.6–14 A total of 10 792 patients were involved in these RCTs, 10 426 of whom were involved in the WHIMS trials. Follow-up of patients ranged from 4 to 5 years for the WHIMS trials6–11 and from 2 weeks to 1 year for the other studies.12–14 These studies indicated a relative decline in cognitive function and an increase in incident dementia in patients in the treatment arms with hormonal therapy (hazard ratio 1.8, 95% confidence interval [CI] 1.2 to 2.6).

Testosterone

Three RCTs studied testosterone use in 144 men, with study follow-up ranging from 3 months to 3 years.16–18 The results were conflicting, with the shortest study of 3 months showing some possible improvement in spatial (p = 0.01) and verbal (p = 0.05) memory.15 Another study indicated worsening in short-term memory (p < 0.05, effect size 0.59) with testosterone treatment at 9 months,16 and the third study showed no significant change in memory-related outcomes over 3 years.17

Dehydroepiandrosterone

Dehydroepiandrosterone (DHEA) is a natural hormone that can be synthetically produced and is frequently marketed as an agent that can prevent cognitive decline.15 Three RCTs16–20 investigated the use of DHEA in a total of 317 patients. Follow-up was from 6 weeks to 1 year. None of the 3 studies showed a statistically significant improvement in cognitive function with the use of DHEA supplements.

Ginkgo

Ginkgo is a popular herbal supplement available worldwide that is thought to have antioxidant effects and to possibly affect neurotransmitters in a manner that is not well characterized.15 Two RCTs have investigated the prevention of cognitive decline with ginkgo.21,22 One that followed 230 cognitively healthy older adults for 6 weeks did not show a significant difference in any cognitive outcome measured.21 Another RCT studied 118 patients over 42 months and also found no significant change in cognitive decline between the ginkgo and placebo groups.22

Vitamins and fatty acids

Randomized controlled trials have assessed the use of various vitamins and fatty acids for the prevention of cognitive decline. Vitamin B6 (n = 76, study duration 12 wk23), vitamin E (n = 6377, study duration nearly 10 yr24), folic acid (n = 24, study duration 4 wk25) and the omega-3 fatty acid EPA–DHA (eicosapentaenoic acid–docosahexaenoic acid; n = 302, study duration 6 mo26) have all been studied, and none showed evidence of preventing cognitive decline.

Miscellaneous pharmacologic interventions

Four RCTs investigated other pharmacologic interventions to determine if they prevent cognitive decline in healthy older adults.27–30 One study examined the effects of candesartan over 4 years among nearly 5000 patients, but no significant change in cognition was noted with its use.27 A second study conducted over 3 years investigated the use of naproxen and celecoxib among 2500 patients and found a marginal decline in memory with use of the medications; global summary scores were 0.05 standard deviations lower (p = 0.02) in the treatment arm.28 A 4-week study of a placebo versus no pill in 40 older adults reported an improvement in delayed recall with placebo (p = 0.035), but review of the CI for the point estimate showed that the result was not statistically significant (CI –0.3 to 1.3).29 Another study investigated AIT-082 (n = 9, follow-up 5 wk), an oral nerve growth factor, which found no significant improvement in memory with intervention.30

Box 1: Evidence for this review

- We searched MEDLINE, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Cochrane Central Register of Controlled Trials from the date of database onset until Oct. 31, 2011, using a list of search terms that included “cognitive decline,” “dementia” and “mild cognitive impairment” (for the full list of terms, see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121448/-/DC1). Our inclusion criteria were randomized controlled trials of pharmacologic or nonpharmacologic interventions in patients aged 65 years and older with normal baseline cognition or mild cognitive impairment. We included studies that investigated any form of cognitive decline, including the development of mild cognitive impairment, progression to dementia or worsening cognitive function on cognitive testing.

- The initial search found 5205 articles, and multiple levels of screening yielded 32 articles for the review (see Appendix 1 for screening algorithms). We assessed study quality using the criteria developed by the Cochrane Effective Practice and Organisation of Care group (http://epoc.cochrane.org /epoc-methods), which assesses risk of bias. Whereas the overall quality of the literature was moderate, most studies had substantial limitations in methodology or data analysis (see Appendix 2, available at www.cmaj.ca /lookup/suppl/doi:10.1503/cmaj.121448/-/DC1).
Do any nonpharmacologic interventions prevent cognitive decline?

One RCT investigating resistance training in healthy older adults showed improvement in cognitive outcomes. There is consistent evidence that cognitive training using formal programs is effective at preventing cognitive decline based on 3 RCTs (Table 1).

Physical exercise
Three RCTs have investigated the role of physical exercise in preventing cognitive decline. Cassilhas and colleagues investigated resistance-training protocols of moderate and high intensity compared with a placebo stretching group in a study involving 62 men over 6 months. The resistance-training protocols consisted of 3 one-hour sessions per week beginning with a 10-minute warm-up and then using varying resistance loads under professional supervision. The authors found a statistically significant improvement in some, but not all, tests of short-term and long-term episodic memory. The authors did not report an overall change in cognition.

A second RCT compared resistance- and balance-training exercises with a flexibility and relaxation program, as well as a no-exercise control. The study, which included 152 healthy older adults who were followed for 1 year, showed no significant improvement in visual, verbal or working memory with the intervention compared with the flexibility and relaxation program, or the no-exercise control.

Baker and colleagues completed a 6-month study with 28 participants comparing aerobic exercise (participants used treadmills, stationary bicycles or elliptical trainers to reach 75%–85% of their heart rate reserve) to stretching (participants carried out stretching and balancing exercises while maintaining their heart rates at or below 50% of their reserve). This study found benefits in executive function ($p = 0.04$) but not in memory in the aerobic exercise group.

Cognitive training
Three RCTs explored the role of various forms of cognitive training, which can also be referred to as mental exercise, to prevent cognitive decline in healthy older adults. Willis and colleagues investigated the role of cognitive training in reasoning, speed or memory in 2802 healthy older adults. All 3 groups showed significant improvements in memory over the 5-year follow-up period, with a relatively greater effect size in the memory-trained group compared with the reasoning- or speed-training groups (effect size 0.23 v. 0.05). The effect size was defined as the difference in improvement from baseline to year 5 between the training and control groups divided by intrasubject standard deviation of the Blom-transformed composite score.

Smith and colleagues compared a computerized cognitive training program based on brain plasticity with a general cognitive stimulation program over 8 weeks in 487 older adults. There was a significant improvement in auditory memory and attention in the treatment group compared with the control group ($p = 0.02$) with an improvement of 2.1 points (3.9 points, 95% CI 2.7 to 5.1, v. 1.8 points, 95% CI 0.6 to 3.0) on a 100-point scale; however, the overlap in CIs

Table 1: Summary of results from randomized controlled trials that investigated the prevention of cognitive decline in healthy older adults

<table>
<thead>
<tr>
<th>Intervention</th>
<th>No. of patients</th>
<th>Study duration</th>
<th>Overall effect on memory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors and NMDA receptor antagonists</td>
<td>89</td>
<td>3–15 mo</td>
<td>None</td>
</tr>
<tr>
<td>Hormonal therapies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrogen</td>
<td>10 792</td>
<td>2 wk–5 yr</td>
<td>Worsened memory</td>
</tr>
<tr>
<td>Testosterone</td>
<td>144</td>
<td>3 mo–3 yr</td>
<td>Inconsistent</td>
</tr>
<tr>
<td>DHEA</td>
<td>317</td>
<td>6 wk–1 yr</td>
<td>Inconsistent</td>
</tr>
<tr>
<td>Ginkgo</td>
<td>348</td>
<td>6 wk–3.5 yr</td>
<td>None</td>
</tr>
<tr>
<td>Vitamins and fatty acids</td>
<td>6 779</td>
<td>4 wk–9.6 yr</td>
<td>None</td>
</tr>
<tr>
<td>Miscellaneous pharmacologic interventions</td>
<td>7 530</td>
<td>4 wk–3.7 yr</td>
<td>Inconsistent</td>
</tr>
<tr>
<td>Physical exercise</td>
<td>244</td>
<td>6 mo–1 yr</td>
<td>Inconsistent</td>
</tr>
<tr>
<td>Cognitive training</td>
<td>3 321</td>
<td>3 wk–5 yr</td>
<td>Improvement</td>
</tr>
</tbody>
</table>

Note: DHEA = dehydroepiandrosterone, NMDA = N-methyl-D-aspartate.
between the treatment and control groups indicates that the significance of the difference is unclear.

Berry and colleagues assessed the impact of 10 hours of computerized visual demonstration training compared with no training in a study of 32 people over 4 weeks. They found statistically significant improvement in performance after 4 weeks in the intervention group compared with the control group ($p < 0.05$, effect size 0.81), not only in the trained perceptual task but also in untrained working memory tasks.

**Modification of vascular risk factors**

We found no RCTs that investigated the modification of vascular risk factors and their impact on the prevention of cognitive decline in healthy older adults. As mentioned, one RCT did look specifically at the use of candesartan and found no significant difference in cognitive outcomes over 4 years. However, we found no RCTs that investigated overall blood pressure control, weight reduction, smoking cessation or other interventions related to reduction of vascular risk factors that may be hypothesized to reduce cognitive decline.

**Limitations and future directions**

This review was limited to English-language studies. We did not include studies involving patients with mild cognitive impairment because this was outside the scope of our review. As with any review, we were limited by the quality of studies available in the literature. Notably, most studies had relatively short follow-up periods for interventions aimed at preventing cognitive decline. Furthermore, several studies selectively reported data and most used numerous end-points, which made the significance of positive results questionable in the setting of many non-significant changes within the same study. The highly variable outcome measures in terms of various tests used to investigate memory outcomes makes it difficult to compare results across studies. One of the most substantial limitations in this review is that the changes observed do not appear to be clinically significant.

A recent Cochrane Review examined cognitively stimulating activities and their role in preventing cognitive decline in older adults with normal cognition or mild cognitive impairment. The study concluded that studies with no-activity controls showed significant improvement, whereas studies with active controls (compared with another intervention) did not reach statistical significance. Our review did not include studies with minimal cognitive impairment; however, one of the 3 studies that investigated cognitive training did use an active control and found a relative benefit to a cognition-based training program.

This review provides some evidence to help clinicians and their patients address what strategies might prevent cognitive decline (Box 2). There is a lack of RCT data on other commonly proposed “anti-aging” strategies, including drinking wine and dietary restrictions, and thus we cannot comment on the potential benefit or harm of these strategies. Future studies should address the impact of cognitive training on the prevention of cognitive decline, and we encourage researchers to consider easily accessible tools such as crosswords puzzles and sudoku that have not been rigorously studied. The studies in this review that assessed cognitive exercises used exercises that were both labour- and resource-intensive, and thus may not be applicable to most patients.

**Conclusion**

We found 32 RCTs of interventions targeted to prevent cognitive decline in healthy older adults, but many were small and had short follow-up periods. None of the studies of pharmacologic agents found clinically or statistically significant benefits associated with their use. More promising results were seen in the studies that assessed cognitive training; all 3 RCTs showed some benefit in the prevention of cognitive decline (Box 2). However, the clinical significance of these results is not clear given that the changes on the cognitive scales used as outcomes in these studies were small. One of 3 studies assessing physical exercise, specifically resistance training, showed some potential benefit of physical training in preventing cognitive decline in healthy older adults.
This review highlights that despite the importance of cognitive impairment, there is not a substantial body of literature addressing how it may be prevented.

References


Affiliations: From the Divisions of Geriatric Medicine (Naqui, Liberhan, Rosenberg, Straus) and General Internal Medicine (Alston), Department of Medicine, University of Toronto, Toronto, Ont.

Contributors: Raza Naqi was involved in the literature search, abstract review, full-text review, data abstraction, manuscript drafting and editing. Dan Liberhan was involved in the abstract review, full-text review, data abstraction and manuscript editing. Jarred Rosenberg and Jillian Alston were involved in the abstract review, data abstraction and manuscript editing. Sharon Strauss was involved in the conception and design of the study and manuscript editing. All of the authors gave final approval of the version submitted for publication.